scholarly journals Cost Analysis of Certolizumab Pegol Compared With Available Biologic Agents For Crohn’s Disease In Mexico And Brazil

2015 ◽  
Vol 18 (7) ◽  
pp. A866
Author(s):  
A Aguirre ◽  
M Naranjo ◽  
H Bierschwale ◽  
M Treglia
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Cost Analysis ◽  
Certolizumab Pegol ◽  
Biologic Agents

T1129 Predictors of Response in Patients with Active Crohn's Disease Treated with Certolizumab Pegol: A Multiple Regression Analysis of PRECISE 2 Data

2008 ◽  
Vol 134 (4) ◽  
pp. A-489-A-490 ◽  
Author(s):  
Stephen B. Hanauer ◽  
Stefan Schreiber ◽  
Ole O. Thomsen ◽  
Gary R. Lichtenstein ◽  
Ralph Bloomfield ◽  
...  
Keyword(s):  
Regression Analysis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Multiple Regression Analysis ◽  
Multiple Regression ◽  
Certolizumab Pegol ◽  
Predictors Of Response

S1058 Certolizumab Pegol Improves Health-Related Quality of Life in Crohn's Disease Patients for Whom Infliximab Treatment Was Not Successful: Results from the WELCOME Study

2009 ◽  
Vol 136 (5) ◽  
pp. A-179 ◽  
Author(s):  
Brian G. Feagan ◽  
William J. Sandborn ◽  
Douglas C. Wolf ◽  
Krassimir Mitchev ◽  
Corinne Jamoul ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Certolizumab Pegol ◽  
Infliximab Treatment ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

Certolizumab Pegol for the Treatment of Crohn's Disease

2007 ◽  
Vol 357 (3) ◽  
pp. 228-238 ◽  
Author(s):  
William J. Sandborn ◽  
Brian G. Feagan ◽  
Simeon Stoinov ◽  
Pieter J. Honiball ◽  
Paul Rutgeerts ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Certolizumab Pegol

A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s Disease

2005 ◽  
Vol 129 (3) ◽  
pp. 807-818 ◽  
Author(s):  
Stefan Schreiber ◽  
Paul Rutgeerts ◽  
Richard N. Fedorak ◽  
Munaa Khaliq–Kareemi ◽  
Michael A. Kamm ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Controlled Trial ◽  
Certolizumab Pegol

scholarly journals Use of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease: Pharmacokinetics Over 6 Weeks in the NURTURE Study

2011 ◽  
Vol 140 (5) ◽  
pp. S-265 ◽  
Author(s):  
Sunny Z. Hussain ◽  
Brian G. Feagan ◽  
Ahmed Samad ◽  
Sylviane Forget ◽  
David L. Sen ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Children And Adolescents ◽  
Certolizumab Pegol

scholarly journals Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn’s Disease

2020 ◽  
Author(s):  
Mark T Osterman ◽  
Kelli L VanDussen ◽  
Ilyssa O Gordon ◽  
Elisabeth M Davis ◽  
Katherine Li ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Epithelial Cell ◽  
Crohn's Disease ◽  
Clinical Response ◽  
Predictive Value ◽  
Controlled Trial ◽  
Biologic Agents ◽  
Intestinal Epithelial ◽  
Randomized Controlled ◽  
Discriminant Ability

Abstract Background Therapeutic efficacy of biologics has remained at about 50% for 2 decades. In Crohn’s disease (CD) patients, we examined the predictive value of an epithelial cell biomarker, ileal microvillar length (MVL), for clinical response to ustekinumab (UST) and vedolizumab (VDZ) and its relationship to another biomarker, intestinal epithelial cell (IEC) pyroptosis, with respect to response to VDZ. Method Ileal biopsies from the UNITI-2 randomized controlled trial were analyzed for MVL as a predictor of clinical response to UST. In a 5-center academic retrospective cohort of CD patients, ileal MVL was analyzed to determine its predictive value for response to VDZ. Correlation between ileal MVL and IEC pyroptosis was determined, and the discriminant ability of the combination of 2 biomarkers to VDZ was examined. Results Clinical response in UST was significantly higher than placebo (65% vs 39%; P = 0.03), with patients with normal MVL (>1.7 µm) having the greatest therapeutic effect: 85% vs 20% (P = 0.02). For VDZ, clinical response with MVL of 1.35 to 1.55 µm was 82% vs 44% (<1.35 µm) and 40% (>1.55 µm; P = 0.038). There was no correlation between ileal MVL and IEC pyroptosis. The combination criteria of ileal pyroptosis <14 positive cells/1000 IECs or MVL of 1.35 to 1.55 µm could identify 84% of responders and 67% of nonresponders (P = 0.001). Conclusion Ileal MVL was predictive of response to UST and VDZ in prospective and retrospective CD cohorts. It was independent of ileal IEC pyroptosis, and combination of the 2 biomarkers enhanced the discriminate ability of responders from nonresponders to VDZ.

Sign in / Sign up

Export Citation Format

Share Document